Myeloma cast nephropathy
Renal · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
AKI in multiple myeloma from free light chains precipitating with Tamm-Horsfall protein forming obstructive tubular casts; often precipitated by dehydration, hypercalcaemia or nephrotoxins.
Figures & algorithms
Red flags
- Severe AKI/oliguria
- Severe hypercalcaemia
- Hyperkalaemia/acidosis needing dialysis
- Cord compression/other myeloma emergencies
Assessment
Differential diagnosis
- Pre-renal AKI
- Hypercalcaemic nephropathy
- Contrast nephropathy
- Light-chain deposition disease
- Amyloidosis
Investigations
- U&E, calcium, FBC, film
- Serum free light chains and protein electrophoresis, urine Bence-Jones protein
- Serum/urine immunofixation
- Renal ultrasound; renal biopsy in selected cases
Management
- Aggressive IV hydration to increase light-chain clearance
- Treat hypercalcaemia
- Stop nephrotoxins (NSAIDs, avoid contrast where possible)
- Urgent haematology referral to start anti-myeloma therapy (e.g. bortezomib-based)
- Consider extracorporeal light-chain removal in selected cases
- Supportive dialysis if needed
Drugs & doses
IV crystalloid (aggressive hydration)
Treat hypercalcaemia (fluids, bisphosphonate)
Anti-myeloma chemotherapy (haematology-led)
Avoid nephrotoxins
Disposition
Admit; haematology and nephrology co-management.
Complications & pitfalls
- Dialysis-dependent renal failure
- Recurrent AKI
- Complications of myeloma
Exam pearls
- Rapid reduction of light chains offers the best chance of renal recovery
- Avoid contrast and NSAIDs
- Suspect myeloma in unexplained AKI with anaemia, hypercalcaemia or bone pain
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.
